Patents by Inventor Heikki Irjala

Heikki Irjala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof
    Patent number: 7910097
    Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: March 22, 2011
    Assignee: Faron Pharmaceuticals Oy
    Inventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi
  • Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof
    Publication number: 20080267958
    Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.
    Type: Application
    Filed: March 5, 2008
    Publication date: October 30, 2008
    Inventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi
  • Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof
    Patent number: 7354577
    Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.
    Type: Grant
    Filed: January 8, 2003
    Date of Patent: April 8, 2008
    Assignee: Faron Pharmaceuticals Oy
    Inventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi
  • Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
    Publication number: 20050069888
    Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.
    Type: Application
    Filed: January 8, 2003
    Publication date: March 31, 2005
    Inventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi